新型取代内酰胺类化合物作为5-HT1A激动剂用于治疗神经精神疾病。
Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.
Abstract
Provided herein are novel substituted lactams as 5-HT1A agonists, pharmaceutical compositions, use of such compounds in treating neuropsychiatric diseases and processes for preparing such compounds.
摘要
本文提供了作为5-羟色胺1A（5-HT1A）激动剂的新型取代内酰胺、药物组合物、此类化合物在治疗神经精神疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.
ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.
2
Novel Substituted Pyrazoles as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.
ACS Med Chem Lett. 2025 Jun 3;16(6):978-979. doi: 10.1021/acsmedchemlett.5c00306. eCollection 2025 Jun 12.
3
Novel Lactams as SARM1 Inhibitors for Treating Axonal Degeneration.
ACS Med Chem Lett. 2025 May 9;16(6):931-932. doi: 10.1021/acsmedchemlett.5c00241. eCollection 2025 Jun 12.
4
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
5
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
6
Novel Piperidine Substituted Pyrazolopyrimidine Derivatives as SGK1 Inhibitors for Treating Cardiovascular Diseases.
ACS Med Chem Lett. 2025 Apr 25;16(5):762-763. doi: 10.1021/acsmedchemlett.5c00217. eCollection 2025 May 8.
7
Novel Substituted Cyclic Compounds as SLC6A19 Inhibitors for Treating Phenylketonuria and Other Amino Acidurias.
ACS Med Chem Lett. 2025 Apr 11;16(5):734-735. doi: 10.1021/acsmedchemlett.5c00177. eCollection 2025 May 8.
8
Novel Substituted Benzimidazole Compounds as TLR9 Inhibitors for Treating Fibrotic Diseases, Particularly Idiopathic Pulmonary Fibrosis.
ACS Med Chem Lett. 2024 Oct 16;15(11):1804-1805. doi: 10.1021/acsmedchemlett.4c00473. eCollection 2024 Nov 14.
9
Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.
ACS Med Chem Lett. 2024 Nov 14;15(12):2093-2094. doi: 10.1021/acsmedchemlett.4c00536. eCollection 2024 Dec 12.
10
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.
ACS Med Chem Lett. 2025 Jan 23;16(2):202-203. doi: 10.1021/acsmedchemlett.5c00019. eCollection 2025 Feb 13.
本文引用的文献
1
5-HT receptors: Pharmacology and functional selectivity.
Pharmacol Rev. 2025 Jul;77(4):100059. doi: 10.1016/j.pharmr.2025.100059. Epub 2025 Apr 23.
2
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Psychopharmacology (Berl). 2025 Apr 11. doi: 10.1007/s00213-025-06777-z.
3
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.
Brain Sci. 2025 Jan 25;15(2):117. doi: 10.3390/brainsci15020117.
4
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
5
Exploring DMT: Endogenous role and therapeutic potential.
Neuropharmacology. 2025 May 1;268:110314. doi: 10.1016/j.neuropharm.2025.110314. Epub 2025 Jan 18.
6
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.
Zotero 插件